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Summary.-The ability of WR-2721 [S-2(3-aminopropylamino)ethyl-phosphoro-
thioic acid] to selectively protect the host against the toxic effects of multiple doses of
cis-dichlorodiammineplatinum [cis-Pt] or cyclophosphamidej [CY] has been studied
in mice and rats bearing 3 different tumours. Selective protection against cis-Pt
induced nephrotoxicity has been demonstrated under all conditions studied, with the
extent of protection being inversely related to the size of the cis-Pt dose. For example,
pre-treatment with 200 mg/kg of WR-2721 30 min before each weekly dose of2 mg/kg
of cis-Pt allows the administration of this cytotoxic agent for 3 times longer before
nephrotoxic injury. In none of these studies was there tumour protection. The same
pattern was observed with CY, but quantitation of the extent of marrow protection
was not possible for the multiple treatment studies, due to the longer latent period
between induced and observed death with this drug. We conclude, therefore, that for
both of these drugs, selective protection of the kidney and marrow is not only main-
tained under conditions of multiple treatment, but actually enhanced due to the need
for smaller doses of cytotoxic agents in these protocols.
UNTIL RECENTLY, the potential useful-
ness of WR-2721 in cancer therapy
appeared limited to radiotherapy, in
which it had been shown to offer selective
radioprotection of a variety of normal
tissues but not ofsolid tumours (see Yuhas,
1980a for review). More recently, however,
it has been shown that WR-2721 could
also offer selective normal-tissueprotection
against a variety of chemotherapeutic
agents, includingnitrogenmustard (Yuhas,
1979) cyclophosphamide (CY) (Yuhas,
1980b; Wasserman et al., 1980) and cis-
dichlorodiammineplatinum (II) (cis-Pt)
(Yuhas & Culo, 1980) whilst leaving the
tumours to suffer the full effects of the
injected chemotherapeutic agents. In both
forms of therapy, we assume that protec-
tion is mediated via interference with
free-radical reactions, and that the basis
of the selective protection of the normal
tissues is selective concentration of WR-
2721 by most normal tissues (Yuhas,
1980b).
Although the ultimate mechanism of
protection may be the same in the two
forms of therapy, it does not necessarily
follow that the extent and kinetics of
protection will be the same in radiotherapy
and chemotherapy, due to differences in
the nature and amplification ofthe induced
injury. These differences are particularly
important when one proceeds from the
laboratory demonstration of selective nor-
mal-tissue protection against single treat-
ments to the more realistic multiple-
treatment protocols which might be used
clinically. Radiotherapy experiments with
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mice have indicated that use of multiple
daily treatments involving injection of
WR-2721 before each exposure does not
produce tumour protection (Echols, 1974;
TsukiYama & Ohshima, 1979) but the
protection by this drug of normal tissues
remains essentially unaltered (Echols,
1974; Echols & Yuhas, 1976; Utley et al.,
1976; and Tsukiyama & Ohshima, 1979).
Unfortunately, similar experiments have
not been performed into the potential
application of WR-2721 in chemotherapy,
and it could be reasonably argued that the
effectiveness of this drug would be either
increased or decreased by multiple treat-
ments.
The possibility that the effectiveness
would be greater with multiple treatments
was suggested by the shape of the toxicity
dose response curves in control and pre-
treated animals given cis-Pt (Yuhas &
Culo, 1980). The slope relating peak blood
utirea nitrogen or BUN, an indicator of the
extent of nephrotoxicity, to cis-Pt dose
is the same in control and WR-2721-
pretreated rats, but the curve for the latter
is shifted to a higher dose range. This
suggests that WR-2721 pretreatment
"neutralizes" an absolute amount ofcis-Pt
(perhaps by a direct interaction between
the 2 drugs) and that after this amount
is exceeded the animals respond to further
increases in dose as if they had not been
given WR-2721. If this were true, protec-
tion against smaller, repeated doses would
be larger than that against a single large
dose, and multiple-treatment protocols
would be more effective therapeutically.
Alternatively, chemotherapeutic injury
could interfere with the ability of normal
tissues to actively concentrate WR-2721
or to respond to its protective influence
(Yuhas, 1980b) suchthatprotectionagainst
each treatment would decline with in-
creasing numbers of treatments. Further,
injury to the tumour could alter its
inability to absorb WR-2721, such that
tumour protection could appear as the
number oftreatments increased.
In order to resolve these questions and
determine whether the potential applica-
tion of WR-2721 in chemotherapy persists
under conditions comparable to those
which would be encountered in the clinic,
we have studied the ability of WR-2721
to protect mice and rats and the tumours
they bear against the toxic effects ofcis-Pt
and CY, when the treatments were given
as single doses, as 5 daily doses, or as
weekly to semi-weekly doses. From the
data presented below, it is readily ap-
parent that tumour protection was not
detectable under any of the experimental
conditions, but that protection of the two
normal tissues studied was greater in the
multiple-treatment protocols than in the
single-treatment studies.
MATERIALS AND METHODS
Animals. Female BALB/c mice andFisher
344 rats were purchased commercially (The
Jackson Laboratory, Bar Harbor, Maine and
Charles RiverBreedingLaboratory,Waltham,
Massachusetts, respectively) and were housed
5 per cage with food and chlorinated water
provided ad libitum. All treatments were
initiated at 75-100 days of age, with tumour
transplants, where appropriate, being given
1-3 weeks earlier.
Tumours.-Two rat (3M2N and DMBA-14)
and one mouse (MCa-11) mammary car-
cinoma were used in these studies. Details of
the origin and maintenance of these tumours
have been provided elsewhere (Yuhas et al.,
1978b). Tumours were harvested from s.c.
transplants, prepared as single-cell suspen-
sions and injected s.c. (1-5 x 106 cells) into
the right hind leg. When the tumours had
reached 7 mm (mice) or 10 mm (rats) in
diameter treatment was started. Result
similar to those presented below have been
obtained with tumours as small as 2-3 mm.
Following treatment, the tumours were
increased thrice weekly until the animals died
or the mean diameter exceeded 20 mm (mice)
or 30 mm (rats). Data are expressed as the
treatment induced delay in time to reach a
given size (i.e., the time required by treated
mice minus the time required by controls).
In certain of the studies we assayed the
absorption of WR-2721 by normal tissues
and tumours in control and treated animals.
For these studies the animals received a dose
of 200 mg of WR-2721/kg body weight,
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including 10 ,uCi of 35S-labelled WR-2721,
kindly provided by Dr Lee Washburn, Oak
Ridge Associated Universities. In brief, 30
min after the i.p. injection of WR-2721 the
animals were bled and killed, and the serum,
tumour and selected normal tissues were
harvested for analysis of absorbed WR-2721,
according to standard methods described
elsewhere (Yuhas, 1980b).
Drugs.-WR-2721, or S-2(3-aminopropyl-
amino)ethylphosphorothioic acid (Sample
AN), was kindly provided by Dr Melvin
Heiffer, Walter Reed Army Institute of
Research. In terms of both host toxicity
(Table I) and protection, this sample gave
results identical to those obtained with a
sample provided by Dr Robert Engle, Drug
Development Branch, NCI. However, both
of these samples were far less toxic than a
Japanese sample of WR-2721 (YM-08310)
obtained from Dr Marvin Sodicoff, Temple
University. We are currently investigating
the basis of this difference in toxicity.
The drug was dissolved in distilled water
(20 mg/ml) immediately before use and in-
jected in a volume equal to 0 5 ml/100 g body
weight (rats) or 1 ml/100 g body weight
(mice). For determination of the LD50 dose,
5 groups of 10 (single dose) or 5 (daily and
weekly doses) animals each were given graded
i.p. doses of WR-2721, with mortality being
recorded up to the 30th day after injection.
For studies in protection against chemo-
therapeutic agents, doses of 25-300 mg/kg
of WR-2721 were given i.p. 30 min before
similar injection of the chemotherapeutic
agents.
Cis-Pt (Platinol; Bristol Laboratories,
Syracuse, New York) was dissolved in dis-
tilled water (2 mg/ml or less) and injected
i.p. in volumes as listed above for WR-2721.
Cyclophosphamide (CY) was kindly provided
by Dr Robert Engle, Drug Development
Branch, National Cancer Institute. This drug
was dissolved in distilled water (20 mg/ml)
immediately before use and injected i.p. as
above.
Toxicity Assays.-Host toxicity to injected
cis-Pt was evaluated in terms ofthe elevation
ofthe blood ureanitrogen (BUN) as described
earlier (Yuhas & Culo, 1980). Peak BUN
levels were observed on the 5th day after
single cis-Pt injections, and 2 days after the
last of 5 daily exposures, in both species. For
the weekly-treatment studies, we did not
study the peak BUNs, but rather the residual
BUN 7 days after treatment (i.e. just before
the next treatment). Due to the chronic
nature of the nephrotoxic injury in these
weekly studies and the consequent inter-
animal variability, we express our results in
terms of the fraction of animals within a
group whose BUN was >40 mg/100 ml, as
opposed to the peak BUN levels used in our
other studies. In our experience with weekly
treatments, once an animal manifests a BUN
>40 mg/100 ml, it does not return toward
normal, but progresses to the eventual death
ofthe animal.
The toxicity of CY was measured solely
in terms ofthe death ofthe host. It should be
noted, however, that Wasserman et at. (1980)
have found that WR-2721 can increase
the resistance of the haematopoietic tissues
ofthe mouse to CY by a factor of2-5 or more,
when injury is measured in terms ofhaemato-
poietic colony-forming units. On the basis of
the well-known toxicity of CY for the blood-
forming tissues, and Wasserman's observa-
tions, we assume that protection against CY-
induced lethality in our studies is a reflection
of haematopoietic protection.
RESULTS
Table I summarizes the estimated
single-dose LD50 values for WR-2721 in
mice and rats, and these are close to our
earlier estimates (Yuhas & Culo, 1980).
TABLE I.-Background data on WR-2721
Chemical formula H2N(CH2)3NH(CH2)2SP03H2
LD5o, rats 524 + 21 mg/kg
LD50, mice 738 + 32mg/kg
When WR-2721 was given daily for 5
days, doses as high as 250 mg/kg/daykilled
no rats (0/5), but doses of 300 mg/kg/day
(1/5) and 350 mg/kg/day (5/5) did so. In
mice, the same range of doses (150-350
mg/kg/day in 50 mg/kg/day increments)
killed none. Weekly doses of 200 mg/kg/
week for 17 weeks killed no rats (0/5).
Similarly all the mice survived doses of
350 mg/kg/week and 200 mg/kg twice per
week, both for 20 weeks. Further, at the
termination of these experiments, we
detected no toxicity in terms of gross
appearance, body weight, haematocrit,
BUN or complete gross and limited micro-
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scopic examination. Due to limited sup-
plies of WR-2721, these multiple-dose
toxicity studies were not expanded further.
Single-dose cis-Pt studies
In order to confirm our original esti-
mates of WR-2721's ability to protect
against cis-Pt nephrotoxicityandtoextend
the WR-2721 dose range down to 100
mg/kg, we gave doses of 100 and 200
mg/kg of WR-2721 to mice and rats and
30 min later gave second injections of
graded doses of cis-Pt. On Days 3, 5 and
7 after treatment the animals were bled
and the BUN determined. As reported
elsewhere for rats (Yuhas & Culo, 1980) and
observed in the present studies for both
species, the peak BUN occurred on Day 5
after treatment, and we have used these
peak BUNs to estimate the extent of pro-
tection against nephrotoxicity in WR-
2721-pretreated animals. The cis-Pt dose
required to elevate the BUN to 40 mg/100
ml was estimated by linear interpolation,
and the standard error of this estimate
from the reciprocal of the slope. The dose-
reduction factor or DRF is defined as the
ratio of cis-Pt doses required to produce
a peak BUN of 40 mg/I00 ml in pre-
treated and control animals. Table II
summarizes the results of these studies,
and demonstrates that protection against
cis-Pt nephrotoxicity is roughly a linear
function of WR-2721 dose in both species.
Data to be presented elsewhere will show
that WR-2721 is protective for all normal
tissues in which cis-Pt and CY toxicity
can be detected.
One month after treatment of the rats
with cis-Pt, they were killed and the
kidneys were processed for histological
examination according to methods des-
cribed elsewhere for radiation studies (Jor-
dan et al., 1979). Tubular degenerative
changes at the corticomedullary junction,
with enlargement of tubular epithelial
nuclei, were the most significant histo-
pathological changes, and are consistent
with the report of Ward & Fauvie (1974).
The number of abnormally small renal
tubules at the corticomedullary junction
was graded 1 to 4+, as were the number
of large tubular nuclei, the resultant
scores being added to obtain a composite
grade. The WR-2721-pretreated ratswhich
survived a given dose of cis-Pt showed far
less renal tubular injury than did controls
given the same cis-Pt dose. As an example,
control rats given 5 mg/kg of cis-Pt
manifested a mean tubular degeneration
score of 5*4 + 0 40, whereas rats pre-
treated with WR-2721 and then given the
same cis-Pt dose showed an injury grade
of 2-25 + 0-20. Therefore, the ability of
WR-2721 to protect against the nephro-
toxicity of cis-Pt is not a transient pheno-
menon, but is morphologically detectable
1 month after treatment.
The choice of WR-2721 dose for oth
multiple-treatment studies was to be
based on two opposing considerations: the
maximum repeated dose of WR-2721
which the animals would tolerate, and the
minimum dose which would offer protec-
tion. The toxicity data were provided
above, and we therefore conducted limited
studies to determine the minimally effec-
tive dose of WR-2721. Rats (3 per point)
were given graded doses of WR-2721
(O 300 mg/kg) and 30 min later an injec-
tion of 7-5 mg/kg of cis-Pt. On Day 5 after
treatment, the animals were bled for BUN
determination and their kidneys pro-
cessed for histological examination. The
most significant changes were acute cell
death involving tubular epithelial cells
at the corticomedullary junction. These
were semi-quantitated on a 1-4+ scale.
Fig. 1 is a plot of the peak (Day 5) BUN
and the renal tubular injury grade as a
function of the pretreatment dose of WR-
2721. It should be noted that the histo-
logical grade in these animals, given 7-5
mg/kg of cis-Pt and killed on Day 5 is
lower than the grade given to animals
given 5 mg/kg of cis-Pt (alone) and killed
30 days later. This is a reflection ofthe fact
that the morphologically observable injury
differs qualitatively over this interval, and
one cannot compare Day 5 scores with
Day 31 scores. These data are presently
being extended, especially in terms of the
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proposed use of WR-2721 in combined-
modality therapy (Yuhas 1980c) and will
be reported elsewhere.
ThepeakBUN data (Fig. 1) suggest that
WR-2721 doses as low as 25 mg/kg can
reduce ci8-Pt nephrotoxicity, whereas the
histological gradings suggest that a dose
of 50 mg/kg is required (Fig. 1). Based on
the fact that the maximum tolerated dose
ofWR-2721, given daily for 5 days to rats
and mice, is 250 mg/kg/day and > 350
mg/kg/day, respectively (see above) these
demonstrations of low-dose protection
against nephrotoxicity prompted us to use
a WR-2721 dose of 100 mg/kg/day as a
realistic compromise for both species.
We reported elsewhere (Yuhas & Culo,
1980) that WR-2721 did not protect 3
different tumours (3M2N, 13762 and
R3230AC) against the anti-tumour effects
of cis-Pt injection. These observations
have been confirmed for the 3M2N tumour
following the injection of 200 mg/kg of
4 II
240
220
200 t
180 - \
160 \I
N, 140 -0 11\
120 N
I-
100 N \ \
80 _N\. o
HISTO. GR
60 -
40 BUN
20
0
RADE
4
w
CD
-J
0 2 ° O
I)
XI
o, v v
0 100 200 300 400
WR-2721 DOSE (mg/kg)
FIG. 1.-Peak (Day 5) BUN levels and histo-
logical grade of renal injury in rats given
0-300 mg/kg of WR-2721 30 min before
an i.p. injection of 7-5 mg/kg of ci8-Pt.
WR-2721, and extended to the DMBA-14
tumour of rats and the MCa- 1 tumour in
mice (data not shown). In all these studies,
200 mg/kg of WR-2721 was given 30 min
before injection of graded doses of cis-Pt.
The maximum and minimum DRF values
for tumour protection in these studieswere
1-07 + 0*02 and 0 95 + 0 05, respectively.
Daily cis-Pt
Fig. 2 is a plot of the peak BUN levels,
which occurred 2 days after the last treat-
ment, in mice and rats given 5 daily doses
of cis-Pt, with or without treatment with
100 mg/kg ofWR-2721 30 min before each
cis-Pt dose. In rats, the daily cis-Pt dose
required to raise BUN to 40 mg/100 ml is
1*6 + 0-1 mg/kg/day, whereas in rats given
prior WR-2721 the estimate is 2-8 + 0-2
mg/kg day. This protection can be viewed
in 3 different ways: as a 1 7-foldincrease in
resistance, as an absolute increase in
tolerance of 1-2 mg/kg/day, or as an
absolute increase in the total tolerated
dose of 6 mg/kg. These estimates compare
favourably with the single-dose studies in
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FIG. 2.-Peak BUN levels observed in mice
and rats as a function of the dose of ci8-Pt
received daily for 5 days. (M) = control
rats; (0I) =rats pretreated with 100 mg/kg
of WR-2721 30 min before each ci8-Pt
injection; (*) =control mice; (0) = mice
given 100 mg/kg ofWR-2721 30 min before
each cis-Pt injection.
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TABLE II.-Effectivenes8 of WR-2721 in
protecting rats and mice agiainst elevation
of BUN (Day 5) induced by single doses
of cis-Pt
Species
Rat
Mouse
WR-2721
Dose* (mg/kg)
100
200
100
200
DRFt
1-3+0-1
1-7+0-1
1-2+ 0-1
1-5+001
* Injected i.p. 30 min before i.p. injection ofgraded
doses of cis-Pt.
t Dose reduction factor; the ratio (WR-2721-
pretreated/control) of cis-Pt doses required to raise
the peak BUN to 40 mg/100 ml.
the rat using a similar WR-2721 dose
(Table II).
In mice, WR-2721 pretreatment (100
mg/kg/day) increased the cis-Pt dose
required for a similar BUN elevation from
2-1 + 0*1 to 3*1 + 0.1 mg/kg/day. This
amounts to a 1*5-fold increase inresistance,
a 1 mg/kg/day absolute increase in
tolerance or a 5 mg/kg increase in total
tolerated dose. Again, these estimates of
protection are larger than we found with
the same WR-2721 dose given before
single d,oses of cis-Pt (Table II). In both
species, therefore, use of multiple smaller
daily doses of cis-Pt is associated with an
increase in the level of protection. Al-
though less accurate, due to the nature of
the endpoint, the protection against
lethality correlated with the estimates of
protection based on the BUN system.
In spite of this highly significant pro-
tection against nephrotoxicity, we were
unable to detect any change in response of
the 3 tumours to cis-Pt in WR-2721 pre-
treated mice and rats. Fig. 3 is a plot of
the growth of the MCa-11 carcinoma in
BALB/c mice given 5 daily doses of WR-
2721 (100 mg/kg) and/or cis-Pt. Since the
growth of the tumours in mice given only
WR-2721 was the same as in untreated
controls, these two groups were pooled for
analysis. In mice receiving only cis-Pt,
1 mg/kg/day failed to produce a significant
delay in tumour growth, but 2 mg/kg/day
produced a delay of 6-4 + 0 30 days in the
time required for the tumours to grow
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FIa. 3. Growth of the MCa-11 tumour in
BALB/c mice given no treatment ( x ), 5
daily doses of 1 mg/kg of c8-Pt (@), 5
daily doses of 2 mg/kg of cis-Pt (A),
5 daily doses of 2 mg/kg of ci8-Pt, each
pretreated 30 min earlier with an injection
of 100 mg/kg of WR-2721 (A), ansi 5 daily
doses of 3 mg/kg of cis-Pt, each pretreated
30 min earlier by an injection of 100 mg/kg
of WR-2721 (LO).
32
4 mm beyond their original size (Fig. 3).
Pre-treatment with 100 mg/kg of WR-
2721 before each daily dose of 2 mg/kg of
cis-Pt did not alter the delay induced
(6.8 vs 6 4 days; P<0 70). Due to the
ability of WR-2721 to protect the host
against nephrotoxicity and lethality, how-
ever, we were able to give them 5 daily
doses of 3 mg/kg, a treatment schedule
which would have otherwise been lethal;
i.e. all mice given 3 mg/kg/day of cis-Pt
without WR-2721 pretreatment (Fig. 2)
died before the 9th day. In mice given
WR-2721 plus 3 mg/kg/day of cis-Pt, the
growth delay amounted to 12-8 days
(Fig. 3). In other words, at equal levels of
nephrotoxic injury, control mice (2 mg/
kg/day of cis-Pt) are provided a 6-4 day
delay in the growth of their tumours,
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FIG. 4.-Growth of DMBA-14 tumour in rats
given no treatment (x), 5 daily doses of
1*5 mg/kg ofci8-Pt (@), 5 daily doses of 1.5
mg/kg Of ci8-Pt each pretreated 30 min
earlier by injection of 100 mg/kg of WR-
2721 (0) and 5 daily doses of 2-5 mg/kg
Of ci8-Pt each pretreated 30 min earlier
by an injection of 100 mg/kg of WR-2721
(A).
whereas WR-2721-pretreated mice receive
a 12-8 day tumour-growth delay.
The same pattern was found in our
daily-cis-Pt studies in rats bearing the
DMBA-14 mammary carcinoma. Rats
given a daily dose of 1-5 mg/kg of cis-Pt
manifested an 8-9 day delay in tumour
growth (Fig. 4) whether or not they
received 100 mg/kg of WR-2721 before
each cis-Pt treatment. Again, due to the
greater tolerance of WR-2721-pretreated
rats to cis-Pt we were able to administer
an otherwise lethal dose of cis-Pt (2.5
mg/kg/day x 5) and the growth of the
tumour was delayed 24 days. Therefore,
at equal levels of nephrotoxicity the
delay in tumour growth in WR-2721-
treated animals (24 days) is far larger than
was obtained in controls (9 days).
Weekly cis-Pt atudiea
Groups of 5 rats were given weekly
doses of 0 or 2, 3, 4 or 5 mg/kg of cia-Pt,
with or without treatment with WR-2721
(200 mg/kg) 30 min earlier. Just before
each weekly treatment, the rats were
weighed and bled for haematocrit and
BUN assay. In the higher-dose groups
(4-5 mg/kg/week) death was preceded by
a severe weight loss (s 40%), haematocrits
> 60% and BUN levels in the range 100-
300 mg/100 ml. At all lower doses, the
weight loss was less severe ('10-20%),
the haematocrits were erratic (30-60%),
but BUN was in the same range as for the
higher-dose groups. In all animals, death
was preceded by a significant elevation
of BUN, and since this occurred in both
control and WR-2721-pretreated groups,
we conclude that the lethal mechanism in
both groups was nephrotoxicity. Limited
autopsy data support this conclusion.
Fig. 5 is a plot of the average week at
which the BUN rose above 40 mg/100 ml
and the mean survival time vs the weekly
doses of cis-Pt for control rats and those
receiving 200 mg/kg of WR-2721 30 min
before each cis-Pt injection. The highly
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FIG. 5. Mean survival time (circles) and
mean time at which the BUN exceeded 40
mg/100 ml (squares) in rats given weekly
doses of 2-5 mg/kg of cis-Pt only (@, *)
or the same weekly ci8-Pt treatments each
pretreated 30 min earlier by 200 mg/kg of
WR-2721 (O, O-).
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protective effect of WR-2721 in this
weekly dosing study is readily apparent
(Fig. 5), and there are two means available
for expressing the extent of protection.
The first is the standard DRF assay, in
which one compares the cis-Pt doses re-
quired to produce a given level of injury
in WR-2721-pretreated and control rats.
Due to the highly efficient protection
offered by WR-2721, however, we can
make only limited comparisons of this
type. The dose-effect curves overlap only
at the 5 mg/kg/week dose level; i.e. doses
of 4 mg/kg/week to WR-2721-pretreated
animals are less effective than 2 mg/kg/
week in controls (Fig. 5). Calculation of a
DRF at the 5 mg/kg/week level in pre-
treated rats is complicated by the fact
that the mortality data are heavilyaffected
by the interval between induction and
death (i.e. equal survival times in both
groups would raise the apparent DRF) and
the BUN data are similarly affected be-
cause they were not measured at the peak.
For a rough comparison, however, we can
perform the reverse calculation: estimate
the cis-Pt dose to WR-2721 pretreated
rats which produces BUN elevations and
mortality as rapidly as does 2 mg/kg/week
of cis-Pt in controls. Although these
estimates will also be underestimates,
due to the survival time problem, the
underestimation will be smaller due to the
longer periods involved. In order to pro-
duce BUN elevations and mortality as
rapidly in WR-2721.-pretreated rats as in
control rats receiving 2 mg/kg of cis-Pt
per week, 4 5 and 4-1 mg/kg week of
cis-Pt was required. Therefore, the esti-
mated dose reduction factors are 2 2 and
2-0 respectively. In the single-dose system,
pre-treatment with 200 mg/kg ofWR-2721
provided, in the same order, DRFs of
1P7 and 1P4 (Yuhas & Culo, 1980; Table II).
A more accurate statistic, which pro-
vides a slightly different view of WR-
2721's protective effectiveness, is the treat-
ment extension factor (TEF). This is
defined as the ratio of times before WR-
2721-pretreated and control rats reach a
given level of injury, when both are re-
ceiving the same weekly dose of cis-Pt.
Normally we have used a 5000 incidence of
elevated BUN and a 5000 incidence of
mortality. These TEF estimates are 2 8,
2 7, 1-9 and 1 7 for the 2, 3, 4 and 5 mg/kg/
week doses in the BUN assay system, and
3.5, 2-7, 1*8 and 1*8 respectively in the
mortality system. It is readily apparent
from these considerations that protection
decreases with the size of the weekly
cis-Pt dose. At the lowest dose tested,
(2 mg/kg/week) therapy can be continued
2-8-3*5 times longer if the rats are receiv-
ing weekly pretreatments with WR-2721.
Fig. 6 is a plot of the growth of the
3M2N tumour with time in control rats
(including those given only WR-2721.) and
in rats receiving graded weekly doses of
cis-Pt, with or without pretreatment with
200 mg/kg of WR-2721 30 min before
each cis-Pt dose. No change in tumour
sensitivity is apparent, except at the
highest dose tested: 5 mg/kg/week of
cis-Pt. After 10 days, the tumours appear
to be regressing faster in the rats not
pretreated with WR-2721. In fact, how-
ever, this more rapid reduction in tumour
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Fic;. 6. Growlth of the 3M12N tumour in rats
receiving no treatment (x ), weekly doses
of 2 (-), 3-5 (-) or 5 (-) mg/kg of cis-Pt
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A'R-2721 followed 30 min later by 2 (0),
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size is a specific manifestation of a severe
body-weight loss which preceded the death
of these animals on Day 18 + 1-2. At
longer intervals, after the control rats
given 5 mg/kg/week ofcis-Pt had died, the
response of the tumours in WR-2721 pre-
treated rats appeared to decline with
each additional treatment. This is due, in
part, to the use of tumour diameters, i.e.
a similar fractional tumour-cell kill would
produce a larger change in tumour dia-
meter in large tumours than in small ones.
Even after correcting the data for this
factor, however, it remained apparent that
response to each individual cis-Pt treat-
ment was declining as treatment con-
tinued. In addition to the possibility that
the tumours were gradually becoming
responsive to the protective action of
WR-2721 under continued treatment, we
considered 2 other possibilities: that
tumour-immune reactions were contribut-
ing to the tumour response in early phases
but not in the later phases, after the
animals had been immunosuppressed, or
that continued treatment had selected
for cis-Pt-resistant variants. Since the
ability of these tumours to absorb WR-
2721 was not affected by prolonged treat-
ment (see below) we considered it unlikely
that true tumour protection was respons-
ible for the declining response of the
tumours, but we wished to test this more
directly. So we harvested 3M2N tumours
which had either received no cis-Pt treat-
ment or had been treated with WR-2721
(200 mg/kg) and cis-Pt (5 mg/kg) weekly
for 5 weeks, 7 days after their last treat-
ment. From both types of tumours we
produced multicellular tumour spheroids
or MTS and determined their sensitivity
to cis-Pt in vitro, according to standard
methods (Yuhas et al., 1978a). MTS
sensitivity was scored in terms of growth
delay as well as "cure", which is equated
with the inability of the MTS to produce
an outgrowth on standard tissue culture
dishes within 30 days. Both assays gave
similar results, summarized in Table III.
It is quite clear that MTS from tumours
treated repeatedlv with cis-Pt are about
TABLE III.-Sensitivity of multicellular
tumour spheroids (MTS) derived from
control and cis-Pt-selected 3M2N tumours
(see text) to in vitro exposure to cis-Pt
[cis-Pt]t
(ug/ml)
0
2
4
8
16
ED50o
Per cent MTS killed*
Ci8-Pt
Control selected
0
9
67
100
100
3-4+0 3 ,ug/ml
0
0
25
50
67
8-1 + 0 9 fig/ml
* 12-19 per point.
t 1 h exposure in vitro.
I Concentration required to kill 50% of the MTS.
twice as resistant to cis-Pt as MTS from
previously untreated tumours. Within
the limits of the experimental data, this
doubling of resistance is sufficient to
account for the declining response of
tumours receiving weekly treatments of
WR-2721 and 5 mg/kg cis-Pt. There
would not appear to be any detectable
tumour protection, therefore, under any
of our cis-Pt protocols.
Distribution of WR-2721 duringc is-Pt
therapy
To determine whether cis-Pt therapy
altered the distribution of WR-2721
during a repeated treatment protocol, we
compared the amount of WR-2721 ab-
sorbed by a series of normal tissues and
tumours 30 min after an i.p. injection of
WR-2721, in the following types of rats:
controls, rats which had received 4 daily
doses of WR-2721 (100 mg/kg) and cis-Pt
(2.5 mg/kg); and rats which had received
5 weekly treatments of WR-2721 (200
mg/kg) and cis-Pt (5 mg/kg). Rats receiv-
ing daily treatments were studied 24 h
after their last treatment, and rats receiv-
ing weekly treatments were studied 1 week
after their last treatment. Although the
daily treatments involved 100 mg/kg/day
of WR-2721, we chose a 200mg/kg dose
of 35S-labelled drug so that all groups
could be compared. In none of these
studies could we detect a changed dis-
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tribution of WR-2721 30 min after injec-
tion due to prior cis-Pt treatments. We
analysed serum, kidney, liver, 3M2N
tumour, brain and lung concentrations of
WR-2721. While the amount of WR-2721
absorbed by an organ is not rigorously
predictive of the level of protection which
will be observed (Yuhas, 1980b) these
studies do indicate that cis-Pt therapy
does not alter the absorptive patterns of
WR-2721, which is consistent with our
observation on the lack of tumour protec-
tion.
Multiple dose CY studies
In an earlier report (Yuhas, 1980b) we
demonstrated that injection of 200 mg/kg
WR-2721 30 min before graded doses of
CY increased the resistance of BALB/c
mice to haemopoietic death by a factor
of 1P5, but did not alter the CY-induced
growth delays of their tumours. It is more
difficult to obtain precise estimates of
protection against CY when it is given
repeatedly, due to the lack of a BUN-type
assay and the longer interval between in-
duction and observation of death in
animals due to haemopoietic failure. For
these studies, therefore, we will not
attempt a comparison ofprotection against
single vs multiple CY treatments, but will
concentrate on the simple questions of
whether WR-2721 does protect the animals
against multiple treatments with CY,
and whether tumour protection can be
detected after multiple CY treatments.
Control BALB/c mice were given either
125 mg/kg of CY twice a week or 200 mg/
kg CY once a week until death, with each
treatment being preceded or not by an
injection of 200 mg/kg of WR-2721 30 min
earlier. In the absence of WR-2721 pre-
treatment these mice died an average of
36+ 3 and 47 + 4 days after the start of
therapy, respectively. If each treatment
was preceded by a WR-2721 injection,
however, these survival times were in-
creased to 61 + 5 and 73 + 4 days. There-
fore,WR-272 1protects miceagainstweekly
doses ofCY.
Fig. 7 is a plot of the growth of the
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FIG. 7.-Growth of the MCa- II tumour in
mice given no treatment (x), twice-
weekly closes of 125 mg/kg of CY ()
once-weekly doses of 200 mg/k,g of CY ()
twice weekly treatments with 200 mg/kg of
WR-2721 followed 30 min later by 125
mg/kg of CY (O) or once-weekly treat-
ments with 200 mg/kg ofWR-2721 followed
30 min later by 200 mg/kg of CY (-).
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MCa-11 tumour in control mice and in
mice receiving the treatments listed above
for non-tumour-bearing mice. No protec-
tion of the tumours is apparent in these
studies, in agreement with the results
listed above for cis-Pt (II) (Fig. 3, 4 and 6).
DISCUSSION
From the data presented above on 3
different tumours growing in mice and
rats, it is quite clear that the ability of
WR-2721 to selectively protect kidneys
and haemopoietic tissue but not tumours
against cis-Pt and CY, respectively, is not
only preserved under conditions of mul-
tiple treatment (daily, semi-weekly, and
weekly), but is apparently enhanced, at
least for cis-Pt. We initially expected this
since it appeared that WR-2721 "neutral-
I
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ized" a constant amount of cis-Pt, as
opposed to being truly dose-modifying
(Yuhas & Culo, 1980). The data presented
above have shown that multiple treat-
ments are associated with larger thera-
peutic gains, but whether ornot a constant
amount of cis-Pt is being neutralized
remains open to question. As an example,
100 mg/kg ofWR-2721 increases resistance
to a single dose of cis-Pt by a factor of 1P3
or by 1P8 mg/kg, according to the way of
viewing the data. If WR-2721 were truly
dose-modifying, we would have expected
the 5 x daily dose required to produce
nephrotoxicity to rise from 1 6 mg/kg/day
to 2 1 mg/kg/day, whereas ifneutralization
of a constant amount of cis-Pt were the
underlying kinetics, we would have expec-
ted this dose to rise to 3-4 mg/kg/day. The
observed value of 2-8 mg/kg/day lies inter-
mediate to these two predictions, so no
conclusions can be reached. Other com-
parisons within the data yield similar
equivocal results, and resolution of this
question will require more precise data.
The observations presented above brings
to 6 the number of tumours which have
failed to respond to the anti-chemotherapy
effectiveness of WR-2721 (see above and
Yuhas, 1979, 1980b; Yuhas & Culo, 1980).
In addition, only one of the 12 tumours
tested (Yuhas, 1980d) has been protected
(DRF= 1-2) against radiation injury. This
tumour, EMT6/Sf, has yielded variable
results in addition to the apparent protec-
tion mentioned above (Utley et al., 1974).
In spite of the fact that this tumour fails
to absorb appreciable quantities of WR-
2721 (Utley et al., 1976) just like other
tumours (Yuhas, 1980d) it is marginally
radioprotected and shows variable results
in chemotherapy. Wasserman et al. (1980)
have independently confirmed the ability
of WR-2721 to offer excellent protection
of the host against cis-Pt and CY, yet in
the same hosts bearing the EMT6/Sf
tumouronefindstumourprotectionagainst
cis-Pt treatment, but no protection against
CY. We conclude, therefore, that failure of
WR-2721 to protect solid tumours against
radiation and/or chemotherapy is fairly
general but unlikely to be universal. This
conclusion is reinforced by the observation
ofWashburn et al. (1974) that at least one
tumour, the Morris 7777 hepatoma, ab-
sorbed WR-2721 readily, and lack of
WR-2721 absorption by tumours is clearly
one of the major factors involved in lack
oftumour protection by this drug (Yuhas,
1980b, d). We are presently investigating
the nature of this absorptive defect
(Yuhas, 1980b; Afzal et al., 1980) and
hopefully will resolve the nature of this
defect and be able to predict which
types of tumours, if any, would be pro-
tected by WR-2721.
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